Yearly Archives: 2009

Bill introduced to repeal Real ID Act

NEW YORK, July 31 — The American Civil Liberties Union issued the following news release:

In a welcome move today, legislation was introduced in the House of Representatives to repeal the discredited Real ID Act of 2005.

The REAL ID Repeal and Identification Security Enhancement Act of 2009, introduced by Representative Steve Cohen (D-TN), would repeal Real ID and replace it with the original negotiated rulemaking process passed by Congress as part of the 9/11 Commission recommendations.

Twenty-five states have already rejected Real ID, citing its high cost, invasiveness and the bureaucratic hassles it creates for citizens.
"Real ID is essentially dead. It’s time for it to be formally repealed and replaced with a process that works, one that protects civil liberties and license security," said Michael Macleod-Ball, Acting Director of the ACLU Washington Legislative Office. "Rep. Cohen took a big step forward by moving to eliminate this failed law and providing much-needed safeguards for our civil liberties."

The Real ID Act of 2005 directs states to issue a federally-approved driver’s license or other form of ID that would be necessary for airline travel and become part of a national database. Like state governments from coast to coast, the American Civil Liberties Union has long opposed the Act as too invasive, too much red tape and too expensive.

Fifteen states have passed binding legislation prohibiting participation in the Real ID program: Alaska, Arizona, Georgia, Idaho, Louisiana, Maine, Minnesota, Montana, New Hampshire, Oklahoma, South Carolina, Virginia, Washington, Oregon, and Missouri.

Ten other states have enacted resolutions in opposition to Real ID: Arkansas, Colorado, Hawaii, Illinois, Missouri, Nebraska, Nevada, North Dakota, South Dakota and Tennessee.

Similar to the Akaka-Sununu Senate bill of 2007 and the Allen House bill of 2007, Rep. Cohen’s bill would eliminate most of the requirements that laid the foundation for a National ID card, such as the obligation that all data and systems be standardized.

The proposal also requires a collaborative approach, called negotiated rulemaking, which would advise the Department of Homeland Security on how to maximize driver’s license security while minimizing the administrative burden on the states.

This approach was initially adopted by the law which implemented the 9/11 Commission recommendations and subsequently repealed by Real ID.

Significant privacy protections in the proposal include prohibiting the use of license data by third parties, encryption of the data and adherence to state privacy laws that may provide greater protection.

Additionally, Rep. Cohen’s bill would also provide for the establishment of a negotiated rulemaking committee, which would present its recommendations to the Department of Homeland Security.

"States and ordinary Americans have all rejected a National ID card," said Christopher Calabrese, Counsel for the ACLU Technology and Liberty Project. "Now it’s time for Congress to follow their lead and finally get rid of the Real ID Act by passing Rep. Cohen’s bill."

To learn more about the Real ID Act or read about its history, visit www.realnightmare.org

 

Journey comes to Tulsa

Tulsa Today is pleased to welcome classic rock bands Journey and Night Ranger to the BOK Center this evening for what is sure to be a lively night of great rock and roll.

Journey, who has sold over 47 million records, not only “created the power ballad” (BOK Center), they are a band that has truly survived the test of time.

Tickets for this evening’s show range from $29.50-$79.50 and may be purchased at the BOK Center box office or online at www.bokcenter.com.

Doors are scheduled to open at 6:30p.m. and the show starts at 7:30p.m.  The BOK Center is requesting no audio, video or professional photography, please.
Journey’s new 10-week tour, which has been one of the most anticipated concerts of the year, is scheduled to end with a September 26 concert at New Orleans Arena in New Orleans, LA.

Just wrapping up a July 29-30 performance at Pala Casino in Pala, CA, the group arrives into Tulsa rested and ready to rock.

With this tour, Journey is promoting its 13th studio album, "Revelation," released in June 2008, which hit No. 5 on the Billboard 200 and peaked at No. 1 on the independent albums chart.

The Platinum-certified release is also the first to feature new lead singer Arnel Pineda, who is based in the Philippines.

“In early December 2007, Journey announced that the Manila-born vocalist would be the most recent replacement for original singer Steve Perry, who left the band after a hip injury suffered in 1997 prevented him from touring.

In the decade since Perry’s departure, several vocalists have filled in for him on the band’s tours and albums.” (Ticketnews.com)

For more information on this event, visit the BOK Center website at http://www.bokcenter.com/events.asp?id=11&pid=171&task=display

Hear some great utube recordings here: site one and site two.

Journey’s official website: http://www.journeymusic.com/home

 

Clinical trial seeking volunteers

Wednesday, 05 August 2009
REDMOND, Wash.– Oklahoma State University issued the following news release: Spiration, Inc., a developer of novel medical devices designed to benefit patients with acute and chronic conditions of the lung, announced today that several new clinical sites are now actively recruiting patients for participation in a pivotal trial of the company’s minimally invasive treatment for severe emphysema.

These sites include Oklahoma State University Center for Health Sciences, Tulsa, Okla., Akron General Medical Center in Akron, Ohio; Medical College of Wisconsin in Milwaukee, Wis.; National Jewish Health in Denver, Colo.; New York-Presbyterian Hospital/Columbia University Medical Center in New York, N.Y.; Southern Illinois University School of Medicine in Springfield, Ill.; University of Iowa Health Care in Iowa City, Iowa; University of California, San Diego Medical Center; the University of Chicago Medical Center; the University of Florida in Gainesville, Fla.; and the University of Washington Medical Center in Seattle, Wash.

"We’re very excited about the addition of these well-respected sites to the first-rate hospitals already participating in the IBV Valve Trial," said Rick Shea, president and CEO, Spiration.

"The approximately 30 sites actively enrolling patients in the study are leaders in their communities helping to advance medical research that may one day improve the lives of people with emphysema, a debilitating condition that severely impacts quality of life."

Other sites now actively recruiting patients for the study include:

Alexian Brothers Medical Center, Elk Grove Village, Ill.

Cleveland Clinic, Cleveland, Ohio

Emory Healthcare, Atlanta, Ga.

Franciscan Health System Research Center, Tacoma, Wash.

Franklin Square Hospital Center/Pulmonary & Critical Care Associates, Baltimore, Md.

HealthPartners, St. Paul, Minn.

Lehigh Valley Health Network, Allentown, Pa.

Mount Sinai Medical Center, New York, N.Y.

Oklahoma State University Center for Health Sciences, Tulsa, Okla.

Pulmonary Associates of Mobile, P.C., Mobile, Alabama

Rhode Island Hospital, Providence, R.I.

Ronald Reagan UCLA Medical Center, Los Angeles, Calif.

Sarasota Memorial Hospital, Sarasota, Fla.

Scott & White Memorial Hospital, Temple, Texas

University of Alabama at Birmingham, Ala.

University of California Davis Medical Center, Sacramento, Calif.

University of Louisville, Louisville, Ky.

University of Pennsylvania Health System, Philadelphia, Pa.

University of Utah, Salt Lake City, Utah

University of Texas Health Science Center at San Antonio, Texas

University of Virginia Health System, Charlottesville, Va.

About the IBV Valve Trial
The pivotal trial to treat patients with emphysema will generate safety and effectiveness data for submission to the U.S. Food and Drug Administration (FDA). This prospective, randomized, blinded clinical trial will enroll up to 500 patients at up to 50 sites in the United States.

Study investigators are still actively recruiting patients for the IBV Valve Trial. The study is open to men and women age 40 to 74 who have been diagnosed with predominantly upper lobe emphysema and shortness of breath with exertion.

Eligible patients must be able to participate in pulmonary function and standardized exercise tests, have not smoked for four months and be willing to not smoke during the trial. Additional criteria must be met for participation in the study. For more information, including a complete list of trial site locations, please visit www.emphysematrial.com or call 877-54-STUDY (877-547-8839).

About the IBV Valve System

The IBV Valve System is a minimally invasive treatment that has diverse applications in both acute and chronic conditions of the lung. During the minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the bronchial tubes through the mouth or nose) to deploy the small umbrella-shaped valves into the airways of the lungs. The valves are designed to be easily removed via a similar bronchoscopic procedure.

The device has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) to control prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged, following lobectomy, segmentectomy, or lung volume reduction surgery. The effectiveness of this device for this use has not been demonstrated.

The IBV Valve System is currently under investigation in the U.S. as a new treatment option for the many people with severe emphysema who do not respond well to current medical therapies or are not eligible for or elect not to undergo invasive surgery such as lung volume reduction or lung transplantation.

The IBV Valve System is marketed and distributed by Olympus in Europe, where the system has received market clearance through the CE Mark for the treatment of diseased and damaged lung, an indication that includes the treatment of emphysema and the control of prolonged air leaks. Olympus also has development and distribution rights for the IBV Valve System in Japan.

About Spiration, Inc.
Spiration, Inc. is committed to improving quality of life for patients with acute and chronic conditions of the lung through the development of novel therapies. Founded in 1999 in Redmond, Wash., the privately held company is backed by prominent investors including Three Arch Partners, New Enterprise Associates, Versant Ventures, New Leaf Ventures (Sprout Group), InterWest Partners, Investor Growth Capital, Saints Capital and Olympus Medical Systems Corp. For more information, visit the company’s website at www.spiration.com.

Information about the U.S. pivotal study of Spiration’s IBV Valve System may be found at www.emphysematrial.com.

Caution: The IBV Valve is not yet approved for use in emphysema, but is subject to an ongoing clinical investigation in which approval for use in emphysema will be sought. The IBV Valve is a Humanitarian Use Device authorized by Federal (or United States) Law for the control of prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy, or lung volume reduction surgery. The effectiveness of this device for this use has not been demonstrated.

Photo credits: general stock photo on web

Last Updated ( Wednesday, 05 August 2009 )

Freedmen Association hosts meeting Saturday

Wednesday, 05 August 2009
The Descendants of Freedmen Association will host their next meeting on Sat., Aug. 8, 2009 in Muskogee Oklahoma.

The meeting will be held beginning at 1pm at Elliot Park.  Attendants are asked to bring a "covered dish" to share with other meeting attendants. Meeting attendants will be updated about the recent naacp national conference.

For more information on the meeting, please contact Mister Graham: 918-756-5886 or Mrs Vann: 405-818-5360.  Immediately following the Descendants meeting will be a meeting of the Cherokee freeedmen band of OKlahoma.

Meeting attendants will be updated on recent events in Washington DC as well as federal case updates.

For more information on the meeting, please contact Mrs Vann: 405-818-5360 or Mister Hightower: 918-360-2029

Both meetings are free and open to the general public of all races, creeds, colors and tribal affiliations.

Last Updated ( Wednesday, 05 August 2009 )

Inhofe appoints Tulsa native to staff

Wednesday, 05 August 2009
WASHINGTON, D.C. – U.S. Senator James M. Inhofe (R-Okla.) today announced the addition of a new staff member in his Washington office. Joel Starr, a Tulsa native, joins the office as Legislative Assistant and Counsel to the Senator on issues pertaining to Inhofe’s recent appointment to the Senate Foreign Relations Committee.

“As a native Oklahoman, I am very proud to join the Inhofe team,” Starr said. “Senator Inhofe will play a vital role on the Senate Foreign Relations Committee.  I look forward to using my professional foreign relations experience to assist him on this new committee assignment.”

Starr most recently served as the Deputy Assistant Secretary for Legislative Affairs at the Department of State.  He was responsible for relations between the U.S. House of Representatives and the Department of State.

Immediately before this position, Starr served as Acting Deputy Assistant Administrator for Legislative Affairs at the U.S. Agency for International Development (USAID).

He has also previously served as Counsel and foreign affairs Legislative Assistant to Congressman Tom Campbell of California, and as an Attorney/Advisor to Housing and Urban Development Secretary Jack Kemp.

Starr is a Major in the Judge Advocate General’s Corps, U.S. Army Reserve, and is a member of the 151st Legal Support Organization out of Alexandria, Virginia.

He is a graduate of Westminster College, the University of Oklahoma and Harvard University.

Last Updated ( Friday, 21 August 2009 )